It is well known that AR inhibitors may lead to initial response in advanced prostate cancer; however, the disease sometimes progress to castration-resistant prostatic cancer (CRPC), and both our patients represent a clear example of such a possibility. This evidence concerns the gene AR and prostate carcinoma.